Heart Failure

Featured Article

The Connection Between Cardiovascular Disease and Sleep Apnea: An Expert Interview

The Connection Between Cardiovascular Disease and Sleep Apnea: An Expert Interview

To examine the link between cardiovascular disease and sleep apnea, The Cardiology Advisor spoke with cardiologist Seth S. Martin, MD, MHS, FACC, FAHA and sleep specialist Rachel Marie E. Salas, MD, FAAN.

Latest Features

The Connection Between Cardiovascular Disease and Sleep Apnea: An Expert Interview

The Connection Between Cardiovascular Disease and Sleep Apnea: An Expert Interview

To examine the link between cardiovascular disease and sleep apnea, The Cardiology Advisor spoke with cardiologist Seth S. Martin, MD, MHS, FACC, FAHA and sleep specialist Rachel Marie E. Salas, MD, FAAN.

Managing Heart Failure: Improving Quality of Life and Preventing Excerbations

Managing Heart Failure: Improving Quality of Life and Preventing Excerbations

Heart failure is the number 1 reason for patient re-admittance to acute-care facilities according to the American Heart Association.

Preventing Heart Failure One Risk Factor at a Time

Preventing Heart Failure One Risk Factor at a Time

Avoiding 3 major risk factors for heart failure—hypertension, diabetes, and obesity—may reduce the likelihood of heart failure development.

Hope for Heart Failure in Thyroid Hormone Therapy

Hope for Heart Failure in Thyroid Hormone Therapy

Subclinicial hypothyroidism has been associated with an increased risk for coronary heart disease events and mortality.

Premature Ventricle Contractions in Heart Failure: A Closer Examination

Premature Ventricle Contractions in Heart Failure: A Closer Examination

A primer on premature ventricle contractions with commentary from 2 arrhythmic/heart failure experts.

ARVD/Cardiomyopathy: Interview with Expert Hugh Calkins, MD

ARVD/Cardiomyopathy: Interview with Expert Hugh Calkins, MD

While ARVD/C management has greatly improved, more precautions—particularly in genetic testing and exercise—need to be taken.

Clinician Viewpoints on the "2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure"

Clinician Viewpoints on the "2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure"

Drs Tauras and Patel from Montefiore Medical Center in the Bronx, New York weigh in on what the new heart failure therapeutic guidelines mean for practicing clinicians.

Managing Cardiovascular Complications of Oncology Treatment

Managing Cardiovascular Complications of Oncology Treatment

Clinicians seek stronger collaboration between cardiology and oncology as well as evidence-based treatment guidelines.

Ixmyelocel-T Cell-Based Therapy Reduced Cardiac Events in Heart Failure

Ixmyelocel-T Cell-Based Therapy Reduced Cardiac Events in Heart Failure

Ixmyelocel-T therapy reduced clinical cardiac events and improved patient outcomes.

Better Late Than Never: Exercise as Primary and Secondary Prevention in CVD

Better Late Than Never: Exercise as Primary and Secondary Prevention in CVD

Exercise's potential positive effects on cardiovascular disease and heart failure may be possible regardless of frequency and time of initiation.

Latest News

Sacubitril/Valsartan vs Enalapril for Physical Activity Improvement in HFrEF

Sacubitril/Valsartan vs Enalapril for Physical Activity Improvement in HFrEF

Sacubitril/valsartan was associated with greater improvements in physical and social activities in patients with heart failure with reduced ejection fraction than enalapril.

Sacubitril/Valsartan May Help Preserve Kidney Function in Patients With HFrEF

Sacubitril/Valsartan May Help Preserve Kidney Function in Patients With HFrEF

Compared with the enalapril-treated group, those treated with sacubitril/valsartan were found to have significantly slower kidney decline (-1.3 vs -1.8mL/min/1.73m2 per year; P<0.0001).

ACC and AHA Release 2018 Quality Measures for Cardiac Rehabilitation

ACC and AHA Release 2018 Quality Measures for Cardiac Rehabilitation

New Class 1 recommendations involve the referral of inpatients and outpatients to cardiac rehabilitation programs that include exercise training.

Elamipretide Granted Orphan Drug Status for Barth Syndrome

Elamipretide Granted Orphan Drug Status for Barth Syndrome

The TAZPOWER study is a randomized, double-blind, placebo-controlled Phase 2/3 crossover study evaluating the safety and efficacy of elamipretide (daily subcutaneous injections) in 12 male patients (aged ≥12 years) with genetically-confirmed Barth syndrome.

Entresto Significantly Improves Physical, Social Activity in Heart Failure Patients

Entresto Significantly Improves Physical, Social Activity in Heart Failure Patients

Entresto may improve limitations in physical and social activities in patients with heart failure.

Oral Tx for Transthyretin Cardiomyopathy Meets Primary Endpoint in Study

Oral Tx for Transthyretin Cardiomyopathy Meets Primary Endpoint in Study

Although they acknowledge the preliminary data is subject to further analysis, they say it demonstrates a statistically significant reduction in the combination of all-cause mortality and frequency of cardiovascular-related hospitalizations compared to placebo at 30 months.

Cardiovascular Outcomes of SGLT-2i vs Other Glucose-Lowering Drugs in T2D

Cardiovascular Outcomes of SGLT-2i vs Other Glucose-Lowering Drugs in T2D

A recent study evaluated the effects of SGLT-2i and other glucose-lowering drugs on cardiovascular event outcomes in patients with type 2 diabetes from 6 countries in 3 world regions.

Automated Detection of Atrial Fibrillation Through Smartwatch Technology

Automated Detection of Atrial Fibrillation Through Smartwatch Technology

A Smartwatch band paired with an app records a 30-second single-lead rhythm strip.

Outcomes With Aspirin for Primary Prevention in Heart Failure, Type 2 Diabetes

Outcomes With Aspirin for Primary Prevention in Heart Failure, Type 2 Diabetes

Primary prevention with aspirin may reduce all-cause mortality in patients with heart failure and type 2 diabetes.

LVAD Shared Decision-Making Program Demonstrates Improved Patient Knowledge

LVAD Shared Decision-Making Program Demonstrates Improved Patient Knowledge

A shared decision-making program between patients with end-stage heart failure being considered for destination therapy left ventricular assist device and their caregivers was associated with improvement in patient knowledge.

Sign Up for Free e-Newsletters